SCHEMBL4736063

SCHEMBL4736063

Nc1onc2cccc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.70
KIT P10721 12/20 0.70
FLT3 P36888 15/20 0.66
PDGFRB P09619 6/20 0.66
LCK P06239 2/20 0.61
LYN P07948 2/20 0.61
FLT1 P17948 2/20 0.61
FLT4 P35916 2/20 0.61
BLK P51451 2/20 0.61
ABL1 P00519 1/20 0.61
FYN P06241 1/20 0.61
CSF1R P07333 1/20 0.61
SRC P12931 1/20 0.61
AURKA O14965 1/20 0.53
ROCK2 O75116 1/20 0.53
RPS6KA5 O75582 1/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
RET P07949 1/20 0.53
PIM1 P11309 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4735263 0.92 KDR (0.70) KDRKITFLT3PDGFRBLCK
SCHEMBL1382612 0.91 KDR (0.68) KDRKITFLT3PDGFRBLCK
SCHEMBL1383101 0.89 KDR (0.67) KDRKITFLT3PDGFRBLCK
SCHEMBL5253141 0.87 KDR (0.70) KDRKITFLT3PDGFRBLCK
SCHEMBL1383479 0.87 KDR (0.70) KDRKITFLT3PDGFRBLCK
SCHEMBL1383493 0.87 KDR (0.72) KDRKITFLT3PDGFRBLCK
SCHEMBL4740182 0.86 KDR (0.72) KDRKITFLT3PDGFRBLCK
SCHEMBL4740222 0.86 KDR (0.72) KDRKITFLT3PDGFRBLCK
SCHEMBL4736486 0.86 KDR (0.72) KDRKITFLT3PDGFRBLCK
SCHEMBL5249583 0.85 KDR (0.73) KDRKITFLT3PDGFRBLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed